However, we were able to achieve stable, shRNA-mediated FKBP52 knockdown in 22Rv1 prostate cancer cells (Fig 4A, top panel), which express both full length AR and a constitutively active, truncated AR protein that supports AR-dependent growth in the absence of full length AR activity. Here, AR is linked to prostate carcinoma.